Neurotype Inc.

About:

Medical Device, SaMD, Software, Neurotechnology, Biofeedback, Neurofeedback

Website: https://www.neurotype.io

Twitter/X: neurotypeinc

Top Investors: National Institutes of Health, National Institute on Drug Abuse (NIDA), Yale University, Minnesota Department of Employment and Economic Development

Description:

Medical device focused on treating brain circuits that underlie drug craving caused by environmental triggers for drug use addiction healthcare. People in recovery are constantly reminded of drug use by environmental cues (people, places, things linked to prior drug use), remaining a persistent risk for relapse, overdoses, and diminished life quality. The NeuromarkR platform (headset+software) measures brain signatures of drug craving not currently addressed in gold standard addiction healthcare. NeuromarkR enables targeted interventions to address triggers for craving by tailored psychotherapy that uses Cognitive Behavioral Therapy (CBT) and Mindfulness-Based Treatment (MBT) strategies.

Total Funding Amount:

$1.17M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Minneapolis, Minnesota, United States

Founded Date:

2019-06-13

Contact Email:

scott(AT)neurotype.io

Founders:

Scott Burwell

Number of Employees:

1-10

Last Funding Date:

2023-09-30

IPO Status:

Private

Industries:

© 2025 bioDAO.ai